[1] [3] Caution is advised in patients with severe gastrointestinal disease, including gastroparesis
In the obese trial cohort, 1 mg moved 24-hour ambulatory heart rate by +0.7 bpm at week 24 the peak of the heart-rate curve, and below the placebo arms +0.8. In a healthy lean Phase 1 group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
To determine whether binding to GLP-1R is necessary for the angiogenetic effect of GLP-1(3236), we conducted an affinity pull-down experiment with biotinylated GLP-1(3236
To date, Novo Nordisk and Eli Lilly have dominated the incretin-based drug market
You're spending real money on these compounds, so you deserve to know which ones might not be worth it